Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04291508 · ClinicalTrials.gov registry record · Phase 2
Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery
A Phase 2 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 488
- Enrollment target
NCT04291508: Completed Phase 2 study, sponsored by Massachusetts General Hospital.
NCT04291508 is a Phase 2 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 488 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04291508, a Phase 2 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 488 participants
- Enrollment target
Study Summary
Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with sepsis-induced hypotension or respiratory failure.
Interventions
- DRUG Intravenous Acetaminophen (room temperature)
- DRUG Intravenous Vitamin C (refrigerated)
- DRUG 5% Dextrose (room temperature)
- DRUG 5% Dextrose refrigerated
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 488 participants |
| Start Date | 2021-10-13 |
| Est. Completion | 2023-07-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04291508
The ClinicalTrials.gov registry entry for NCT04291508 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 488 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Intravenous Acetaminophen (room temperature) is the first listed.
NCT04291508 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04291508 about?
NCT04291508 is a clinical study titled "Acetaminophen and Ascorbate in Sepsis: Targeted Therapy to Enhance Recovery". Prospective multi-center phase 2b randomized placebo-controlled double-blinded interventional platform trial of two different pharmacologic therapies (intravenous Vitamin C or intravenous Acetaminophen) for patients with sepsis-induced hypotension or respiratory failure.
What is the current status of trial NCT04291508?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 488 participants. The study started on 2021-10-13. Estimated completion is 2023-07-27.
What interventions are being tested in trial NCT04291508?
The interventions under investigation include: Intravenous Acetaminophen (room temperature) (DRUG), Intravenous Vitamin C (refrigerated) (DRUG), 5% Dextrose (room temperature) (DRUG), 5% Dextrose refrigerated (DRUG).
Who is sponsoring clinical trial NCT04291508?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.